Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma.
Bisphosphonate therapy has been shown to significantly reduce the incidence of skeletal complications in patients with myeloma. Several recent reports have described osteonecrosis of the jaw (ONJ) associated with bisphosphonates. These reports mainly demonstrate an association between ONJ and potent i.v. bisphosphonates. We report a case of ONJ in a patient with myeloma, who had only been treated with oral sodium clodronate. While the degree of risk for osteonecrosis in patients taking oral bisphosphonates, such as clodronate, remains uncertain it would be prudent to consider carefully the indications for the use of these agents to minimise the risk of ONJ.
Montazeri
Amir H
AH
Bone Marrow Transplant Unit, Glasgow Royal Infirmary, Glasgow, UK.
Erskine
J Gordon
JG
McQuaker
I Grant
IG
D000328:Adult; D004002:Clodronic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D010020:Osteonecrosis / Q000139:chemically induced*
D004002:Clodronic Acid